Picture loading failed.

Pre-Made Bapineuzumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Bapineuzumab (nicknamed "bapi")] is a humanized monoclonal antibody that acts on the nervous system and may have potential therapeutic value for the treatment of Alzheimer's disease nd possibly glaucoma. However, in 2012 it failed to produce significant cognitive improvements in patients in two major trials, despite lowering key biomarkers of AD, amyloid brain plaque and hyperphosphorylated tau protein in CSF.[

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-046-1mg 1mg 3090
GMP-Bios-ab-046-10mg 10mg Inquiry
GMP-Bios-ab-046-100mg 100mg Inquiry
GMP-Bios-ab-046-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Bapineuzumab biosimilar, Whole mAb, Anti-APP Antibody: Anti-AAA/AD1/PN2/ABPP/CVAP/ABETA/PN-II/preA4/CTFgamma therapeutic antibody
INN Name Bapineuzumab
TargetAPP
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure4ojf:HL/4hix:HL
Year Proposed2005
Year Recommended2006
CompaniesJANSSEN Alzheimer Immunotherapy;Pfizer;Wyeth;Elan Corporation
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAlzheimer's disease
Development Techna